Bavarian Nordic set to earn $975 million in Prostvac deal

4 March 2015

Danish biotech firm Bavarian Nordic (OMX: BAVA) has granted US pharma major Bristol-Myers Squibb (NYSE: BMY) an exclusive option to license and commercialize Prostvac, its investigational Phase III prostate-specific antigen (PSA)-targeting cancer immunotherapy in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

Bavarian Nordic saw its share price rocket 27.7% to 36.95 Danish kroner this morning following the announcement,

Given that Prostvac gains regulatory approval, it will be the second prostate cancer vaccine to come to market, after that of US firm Dendreon’s Provenge (sipuleucel-T), but the Danish company’s product has shown greater efficacy, rights to which have recently been acquired by Canada’ Valeant Pharmaceutical International (TSX: VRX) from bankrupt Dendreon (The Pharma Letter February 11).

Under terms of the deal with B-MS, Bavarian Nordic could earn as much as $975 million, and will receive an upfront payment of $60 million. B-MS can exercise the option in its sole discretion within a designated time after data is available from the ongoing Phase III trial.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK